A Reversal for bluebird bio Inc Is Not Near. Professional Options Traders Are Bullish

 A Reversal for bluebird bio Inc Is Not Near. Professional Options Traders Are Bullish

In today’s session bluebird bio Inc (BLUE) registered an unusually high (458) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious BLUE increase. With 458 contracts traded and 9054 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: BLUE161021C00070000 closed last at: $5.9 or 55.3% up. About 289,945 shares traded hands. bluebird bio Inc (NASDAQ:BLUE) has risen 54.22% since March 9, 2016 and is uptrending. It has outperformed by 46.80% the S&P500.

Analysts await bluebird bio Inc (NASDAQ:BLUE) to report earnings on November, 2. They expect $-1.48 EPS, down 25.42% or $0.30 from last year’s $-1.18 per share. After $-1.59 actual EPS reported by bluebird bio Inc for the previous quarter, Wall Street now forecasts -6.92% EPS growth.

bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage

Out of 13 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 77% are positive. bluebird bio has been the topic of 26 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by TH Capital on Thursday, November 5. The firm has “Hold” rating given on Friday, June 3 by Cantor Fitzgerald. The firm has “Buy” rating by Goldman Sachs given on Thursday, September 15. As per Friday, October 23, the company rating was initiated by Jefferies. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Equal-Weight” rating given on Tuesday, September 8 by Morgan Stanley. As per Monday, December 7, the company rating was maintained by Jefferies. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Buy” rating given on Thursday, December 17 by Stifel Nicolaus. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock has “Buy” rating given by Zacks on Tuesday, August 11. The firm has “Equal-Weight” rating given on Monday, December 7 by Morgan Stanley.

According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.34, from 1.34 in 2016Q1. The ratio is negative, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
Moreover, Jpmorgan Chase & has 0% invested in bluebird bio Inc (NASDAQ:BLUE) for 85,235 shares. Susquehanna International Grp Inc Ltd Liability Partnership last reported 129,958 shares in the company. Brighton Jones, a Washington-based fund reported 42,371 shares. Moreover, Sei Investments Co has 0% invested in bluebird bio Inc (NASDAQ:BLUE) for 1,217 shares. Moreover, Sphera Funds Mngmt has 0.45% invested in bluebird bio Inc (NASDAQ:BLUE) for 40,000 shares. Legal And General Grp Inc Public Limited last reported 8,314 shares in the company. X Ltd Limited Liability Company owns 90 shares or 0% of their US portfolio. Cap Rech Investors holds 4.52M shares or 0.07% of its portfolio. Quantbot Lp owns 2,848 shares or 0.01% of their US portfolio. Cubist Systematic Strategies Ltd Liability Company owns 290 shares or 0% of their US portfolio. Creative Planning owns 25,801 shares or 0.01% of their US portfolio. First Light Asset Management Limited Liability Corporation owns 67,044 shares or 1.34% of their US portfolio. Axa owns 163,557 shares or 0.03% of their US portfolio. Martingale Asset L P holds 0.01% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 14,208 shares. Cam Gru A S has 0.01% invested in the company for 6,400 shares.

bluebird bio, Inc. is a biotechnology company. The company has a market cap of $2.42 billion. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. It currently has negative earnings. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

BLUE Company Profile

bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

More recent bluebird bio Inc (NASDAQ:BLUE) news were published by: Fool.com which released: “Why bluebird bio, Inc. Stock Soared 37.4% in September” on October 11, 2016. Also Fool.com published the news titled: “Why bluebird bio Inc. Jumped Monday” on September 12, 2016. Fool.com‘s news article titled: “Why bluebird bio Inc. Jumped Again Today” with publication date: September 15, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment